Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.74 |
| ▸ | MTOR | P42345 | 16/20 | 0.74 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.74 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.71 |
| ▸ | PRKDC | P78527 | 4/20 | 0.70 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.70 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 2/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | CSF1R | P07333 | 1/20 | 0.70 |
| ▸ | MET | P08581 | 1/20 | 0.70 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.70 |
| ▸ | LTK | P29376 | 1/20 | 0.70 |
| ▸ | CDK7 | P50613 | 1/20 | 0.70 |
| ▸ | NEK2 | P51955 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 1/20 | 0.70 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.70 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31439397 | 0.89 | PIK3CA (0.57) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL369464 | 0.88 | PIK3CA (0.58) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL31439321 | 0.88 | PIK3CA (0.58) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL8255195 | 0.88 | PIK3CA (0.74) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1071797 | 0.87 | PIK3CA (0.57) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL27914183 | 0.86 | PIK3CA (0.54) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL367402 | 0.85 | PIK3CA (0.55) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL367425 | 0.85 | PIK3CA (0.55) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL927082 | 0.85 | PIK3CA (0.77) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL927255 | 0.85 | PIK3CA (0.77) | PIK3CAMTORPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3788050-B1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| CN-112368289-B | C26-linked rapamycin analogues as MTOR inhibitors | 锐新医药公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| EP-2094700-A2 | SALTS AND CRYSTALL FORMS OF 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-1-YL)-PHENYL]-PROPIONITRILE | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008064093-A2 | SALTS AND CRYSTAL FORMS OF 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-1-YL)-PHENYL]-PROPIONITRILE | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | PIK3CA 60/4885MTOR 1/4885PIK3CD 94/4885 |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PIK3CA 60/4885MTOR 1/4885PIK3CD 94/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PIK3CA 58/4885MTOR 1/4885PIK3CD 142/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3CA 58/4885MTOR 1/4885PIK3CD 142/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | PIK3CA 122/4885MTOR 3/4885PIK3CD 215/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | PIK3CA 8/4885MTOR 89/4885PIK3CD 9/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | PIK3CA 1144/4885MTOR 2/4885PIK3CD 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.